Tallaght University Hospital — Clinical Trial Site

67 Registered trials

35 Currently recruiting

Organisation

Tallaght University Hospital

Location

Dublin 24, Ireland

Identifier

ORG-100032750

Address

Tallaght, D24 NR0A, Ireland

Departments

4801: Clinical Research Facility
8044: Clinical Trial Center
Age Related Healthcare
Clinical Medicine
Clinical Trials Unit
Cognitive Clinical Trials Unit
Critical Care
Department of Medical Oncology
Gastroenterology
Haematology
ICU
Intensive Care Unit
Medical Oncology
Neurology
Oncology
Oncology (TUH)
Oncology Day Unit
Oncology Day Ward
Oncology department
Oncology Haematology Clinical Trials
Oncology/Haematology Clinical Trials
Pulmonary Medicine
Respiratory
Respiratory Medicine
Stroke
Tallaght
Urology

Clinical trials at this site (67)

Search interface

A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 myelodysplastic neoplasms/syndromes (MDS) 5 2025-04-30
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Recruiting

2024-513547-82-00 Transthyretin Amyloidosis 5 2025-03-11
Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting

2023-506288-33-00 Metastatic castration resistant prostate cancer (mCRPC) 9 2025-03-03
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Recurrent or Metastatic Solid Tumors (endometrial cance 9 2025-02-11
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
EPO-TRAUMA Recruiting

2023-506081-31-00 Traumatic Injury 5 2022-03-29
A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss Recruiting

2024-518177-33-00 Cancer Anorexia 7 2021-10-01
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Metastatic Castration-Resistant Prostate Cancer 9 2016-11-17
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and surv… Ended

2024-511306-23-00 Breast cancer, colon cancer, rectal cancer, stomach can 5 2024-07-01
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Renal cell carcinoma 5 2023-11-17
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 dou… Ended

2024-514565-18-00 Localised Very High-Risk Cancer of the Prostate 5 2021-07-20
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Advanced RCC with clear cell component 5 2021-04-19
A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended

2022-502705-15-00 High-risk muscle-invasive bladder cancer 5 2021-03-08
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystecto… Ended

2023-504932-16-00 Muscle Invasive Bladder Cancer 5 2019-06-04